The Life Saving Drugs Program Expert Panel considered this application from Sanofi-Aventis Australia Pty Ltd on 15 November 2019. They deferred their decision until the Government-agreed outcomes from the Gaucher disease LSDP medicines review were known.
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English